Detalhe da pesquisa
1.
Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy.
Breast Cancer Res Treat
; 199(2): 231-241, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36947277
2.
Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial.
Lancet Oncol
; 23(5): 636-649, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35405087
3.
Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS).
Cancer Sci
; 113(9): 3169-3179, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35754298
4.
A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17).
Breast Cancer Res Treat
; 190(3): 425-434, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34554370
5.
Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study).
Invest New Drugs
; 39(1): 217-225, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32833136
6.
Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study.
Jpn J Clin Oncol
; 50(1): 3-11, 2020 Jan 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-31821506
7.
Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer.
Breast Cancer Res Treat
; 178(2): 283-294, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31402409
8.
Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
Breast Cancer Res Treat
; 173(1): 123-133, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30242578
9.
A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study.
Jpn J Clin Oncol
; 48(9): 855-859, 2018 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30020510
10.
[A Phase I Combination Dose-Escalation Study of Eribulin Mesylate and Gemcitabine in Japanese Patients with Metastatic Breast Cancer].
Gan To Kagaku Ryoho
; 45(8): 1165-1170, 2018 08.
Artigo
em Japonês
| MEDLINE | ID: mdl-30158412
11.
Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
Cancer Sci
; 108(5): 987-994, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28256066
12.
First-line bevacizumab plus paclitaxel in Japanese patients with HER2-negative metastatic breast cancer: subgroup results from the randomized Phase III MERiDiAN trial.
Jpn J Clin Oncol
; 47(5): 385-392, 2017 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28158579
13.
Effect of olanzapine for breast cancer patients resistant to triplet antiemetic therapy with nausea due to anthracycline-containing adjuvant chemotherapy.
Jpn J Clin Oncol
; 46(5): 415-20, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26951840
14.
A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer.
Jpn J Clin Oncol
; 46(5): 407-14, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26917603
15.
[Efficacy of Levofloxacin Hydrate in Febrile Neutropenia for Outpatient Chemotherapy].
Gan To Kagaku Ryoho
; 43(5): 593-6, 2016 May.
Artigo
em Japonês
| MEDLINE | ID: mdl-27210089
16.
[The Effectiveness of Polaprezinc Preparation for Taste Alteration in Cancer Chemotherapy].
Gan To Kagaku Ryoho
; 43(8): 979-83, 2016 Aug.
Artigo
em Japonês
| MEDLINE | ID: mdl-27539040
17.
A phase I study of capecitabine combined with CPT-11 in metastatic breast cancer pretreated with anthracyclines and taxanes.
Oncology
; 86(4): 206-11, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24820348
18.
[Subcutaneous implantation type central venous port management in patients with malignant tumors effect of different antiseptic agents on central venous port-related infection].
Gan To Kagaku Ryoho
; 41(8): 981-5, 2014 Aug.
Artigo
em Japonês
| MEDLINE | ID: mdl-25132030
19.
Long-term prognostic value of the GenesWell BCT score in Asian women with hormone receptor-positive/HER2-negative early breast cancer.
Breast Cancer
; 31(1): 31-41, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37812303
20.
A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study).
Int J Clin Oncol
; 18(4): 598-606, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22833344